AR086272A2 - Anticuerpos anti-factor d humanizados y sus usos - Google Patents
Anticuerpos anti-factor d humanizados y sus usosInfo
- Publication number
- AR086272A2 AR086272A2 ARP120101576A ARP120101576A AR086272A2 AR 086272 A2 AR086272 A2 AR 086272A2 AR P120101576 A ARP120101576 A AR P120101576A AR P120101576 A ARP120101576 A AR P120101576A AR 086272 A2 AR086272 A2 AR 086272A2
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- light chain
- factor
- hvr
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La solicitud hace referencia a anticuerpos anti-factor D, sus secuencias de aminoácidos y ácidos nucleicos, las células y vectores que contienen estos anticuerpos y su producción y uso en la preparación de composiciones y medicamentos para el tratamiento de enfermedades y trastornos asociados a una activación excesiva o descontrolada del complemento. Estos anticuerpos son útiles para diagnóstico, prevención y tratamiento de enfermedades.Reivindicación 1: Un anticuerpo anti-factor D que comprende HVR de cadena ligera de un anticuerpo de referencia, donde dicho anticuerpo anti-factor D comprende además una sustitución en una o más posiciones de dicho anticuerpo, donde dicho anticuerpo de referencia comprende HVR-1 de cadena ligera que contiene ITSTDIDDDMN (identificador de secuencia nº 30), cadena ligera HVR-2 que comprende GGNTLRP (identificador de secuencia nº 35) y cadena ligera HVR-3 que comprende LQSDSLPYT (identificador de secuencia nº 38) donde dicha sustitución es una o más de las siguientes: (a) el aminoácido de la posición 33 de la cadena ligera es L o I, (b) el aminoácido de la posición 34 de la cadena ligera es A o Q, (c) el aminoácido de la posición 52 de la cadena ligera es S o A, (d) el aminoácido de la posición 104 de la cadena ligera es V, (e) el aminoácido de la posición 1 de la cadena pesada es E; (f) el aminoácido de la posición 99 de la cadena pesada es A o Q, (g) el aminoácido de la posición 100 de la cadena pesada es A o Q.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4843108P | 2008-04-28 | 2008-04-28 | |
US4868908P | 2008-04-29 | 2008-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086272A2 true AR086272A2 (es) | 2013-12-04 |
Family
ID=40999836
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101490A AR071510A1 (es) | 2008-04-28 | 2009-04-27 | Anticuerpos anti- factor d humanizados y sus usos |
ARP120101576A AR086272A2 (es) | 2008-04-28 | 2012-05-04 | Anticuerpos anti-factor d humanizados y sus usos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101490A AR071510A1 (es) | 2008-04-28 | 2009-04-27 | Anticuerpos anti- factor d humanizados y sus usos |
Country Status (35)
Country | Link |
---|---|
US (7) | US8273352B2 (es) |
EP (3) | EP2283041B1 (es) |
JP (2) | JP5636359B2 (es) |
KR (2) | KR20130084330A (es) |
CN (2) | CN103724433B (es) |
AR (2) | AR071510A1 (es) |
AU (1) | AU2009241348C1 (es) |
BR (1) | BRPI0907701A2 (es) |
CA (2) | CA2908470A1 (es) |
CL (2) | CL2009001001A1 (es) |
CO (1) | CO6331346A2 (es) |
CR (2) | CR20170001A (es) |
CY (1) | CY1116982T1 (es) |
DK (1) | DK2283041T3 (es) |
EC (1) | ECSP10010637A (es) |
ES (1) | ES2552817T3 (es) |
HK (3) | HK1147503A1 (es) |
HR (1) | HRP20151259T1 (es) |
HU (1) | HUE026349T2 (es) |
IL (3) | IL208555A (es) |
MA (1) | MA32300B1 (es) |
MX (2) | MX2010011342A (es) |
MY (1) | MY162350A (es) |
NZ (3) | NZ621103A (es) |
PE (2) | PE20091783A1 (es) |
PH (1) | PH12014500519B1 (es) |
PL (1) | PL2283041T3 (es) |
PT (1) | PT2283041E (es) |
RS (1) | RS54405B1 (es) |
RU (1) | RU2488594C2 (es) |
SG (2) | SG10201608305SA (es) |
SI (1) | SI2283041T1 (es) |
TW (3) | TW201819418A (es) |
WO (1) | WO2009134711A1 (es) |
ZA (1) | ZA201301709B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2998318A1 (en) | 2005-11-04 | 2016-03-23 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
RS58233B1 (sr) * | 2006-11-02 | 2019-03-29 | Genentech Inc | Humanizovana anti-faktor d antitela i njihove upotrebe |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
ES2684475T3 (es) * | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
EP2670847B1 (en) * | 2011-02-03 | 2016-10-05 | XOMA Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
EP2689326B1 (en) | 2011-03-25 | 2022-11-16 | Intel Corporation | Memory fragments for supporting code block execution by using virtual cores instantiated by partitionable engines |
CN104040491B (zh) * | 2011-11-22 | 2018-06-12 | 英特尔公司 | 微处理器加速的代码优化器 |
BR112015005895A2 (pt) | 2012-09-19 | 2017-12-12 | Genentech Inc | método para prevenir ou reduzir a incorporação indevida da norleucina e para produzir uma proteína ou um polipeotídeo em uma célula hospedeira bacteriana, microrganismo, anticorpo anti-vegf ou fragmento de anticorpo anti-vegf, anticorpo anti-fator d ou fragmento de anticorpo anti-fator d e anticorpo anti-met ou fragmento de anticorpo anti-met |
BR112015013861A2 (pt) | 2012-12-18 | 2017-07-11 | Novartis Ag | composições e métodos para proteínas de ação prolongada |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
EP2972836B1 (en) | 2013-03-15 | 2022-11-09 | Intel Corporation | A method for emulating a guest centralized flag architecture by using a native distributed flag architecture |
ES2753419T3 (es) * | 2013-06-07 | 2020-04-08 | Univ Duke | Inhibidores del factor H del complemento |
CA2920666A1 (en) * | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
AU2014332021B2 (en) * | 2013-10-07 | 2020-05-07 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
MA39934A (fr) * | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2017075173A2 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
EP3368565A1 (en) * | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody formulations |
EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
SI3368579T1 (sl) * | 2015-10-30 | 2022-04-29 | F.Hoffmann-La Roche Ag | Tečajni modificirani fragmenti protitelesa in metode priprave |
AU2016344146A1 (en) | 2015-10-30 | 2018-05-10 | Genentech, Inc. | Methods of measuring Factor D activity and potency of Factor D inhibitors |
WO2017075212A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
SG11201803703UA (en) * | 2015-11-24 | 2018-06-28 | Annexon Inc | Anti-complement factor c1q fab fragments and uses thereof |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
WO2017129064A1 (zh) * | 2016-01-28 | 2017-08-03 | 成都康弘生物科技有限公司 | 抗补体因子D的人源化Fab和人源化抗体及其用途 |
JP7170316B2 (ja) * | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
WO2018148486A1 (en) | 2017-02-10 | 2018-08-16 | The Trustees Of The University Of Pennsylvania | Anti-factor d antibodies and uses thereof |
CN106905431B (zh) * | 2017-04-10 | 2020-01-17 | 旭华(上海)生物研发中心有限公司 | 抗人补体d因子的单克隆抗体及其用途 |
EP3610010A4 (en) * | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | COMPLEMENT D-FACTOR ANTAGONIST ANTIBODIES AND THEIR CONJUGATES |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
EP3608674A1 (en) * | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
WO1989005859A1 (en) | 1987-12-21 | 1989-06-29 | The Upjohn Company | Agrobacterium mediated transformation of germinating plant seeds |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
ES2112431T3 (es) | 1992-08-21 | 1998-04-01 | Genentech Inc | Procedimiento para el tratamiento de un trastorno mediado por lfa-1. |
US5861156A (en) | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
ES2236706T3 (es) | 1994-03-23 | 2005-07-16 | Alexion Pharmaceuticals, Inc. | Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal. |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
WO2000037638A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US5897475A (en) | 1994-10-05 | 1999-04-27 | Antex Biologics, Inc. | Vaccines comprising enhanced antigenic helicobacter spp. |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO1999040100A1 (en) | 1998-02-09 | 1999-08-12 | Human Genome Sciences, Inc. | 45 human secreted proteins |
US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
JP2001513576A (ja) | 1997-08-26 | 2001-09-04 | グリアテック インコーポレイテッド | 側副経路を介する補体活性化を阻害するためのプロセス |
US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
PT1481990E (pt) | 1997-11-21 | 2007-09-17 | Genentech Inc | Antigénios relacionados com a-33 e suas utilizações farmacológicas |
EP1054693B8 (en) | 1998-02-20 | 2009-03-04 | Genentech, Inc. | Inhibitors of complement activation |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
CA2340794A1 (en) | 1998-08-27 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
KR100468978B1 (ko) | 1998-12-16 | 2005-02-02 | 제넨테크, 인크. | 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산 |
BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
EP1220905A2 (en) | 1999-03-08 | 2002-07-10 | Genentech Inc. | Composition and methods for the treatment of immune related diseases |
EE05497B1 (et) | 1999-03-11 | 2011-12-15 | Rmf Dictagene S.A. | Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha |
US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
AU2883900A (en) | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2388777A1 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 human secreted proteins |
EP1661997A1 (en) | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
ATE435873T1 (de) | 2000-03-23 | 2009-07-15 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
JP4764590B2 (ja) | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP1325033B1 (en) | 2000-10-10 | 2009-11-25 | Genentech, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
MXPA03003144A (es) | 2000-10-13 | 2004-12-06 | Biogen Inc | Anticuerpos humanizados anti-lt-??-r. |
US20040077575A1 (en) | 2002-01-11 | 2004-04-22 | Giordano Giovan Giacomo | Inhibition of pathological angiogenesis in vivo |
WO2003015819A1 (en) | 2001-08-17 | 2003-02-27 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
US20040152105A1 (en) | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
RU2232991C1 (ru) | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
US7923010B2 (en) | 2003-09-11 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7127355B2 (en) | 2004-03-05 | 2006-10-24 | Perlegen Sciences, Inc. | Methods for genetic analysis |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
KR101290621B1 (ko) | 2004-11-18 | 2013-07-29 | 더 락커펠러 유니버시티 | 안질환 치료용 방법 및 조성물 |
WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
MX2007009565A (es) | 2005-02-14 | 2008-03-10 | Univ Iowa Res Found | Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad. |
WO2006133295A2 (en) | 2005-06-08 | 2006-12-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26 |
CA2625206C (en) | 2005-10-08 | 2021-12-07 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
EP2998318A1 (en) * | 2005-11-04 | 2016-03-23 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
RS58233B1 (sr) | 2006-11-02 | 2019-03-29 | Genentech Inc | Humanizovana anti-faktor d antitela i njihove upotrebe |
US20090111708A1 (en) | 2007-05-11 | 2009-04-30 | Seddon Johanna M | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CA2721503A1 (en) | 2008-04-18 | 2009-12-03 | Massachusetts General Hospital | Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
CA2740242A1 (en) | 2008-11-05 | 2010-05-14 | Genentech, Inc. | Genetic polymorphisms in age-related macular degeneration |
WO2010075519A2 (en) | 2008-12-23 | 2010-07-01 | Massachusetts Eye & Ear Infirmary | Allelic variants associated with advanced age-related macular degeneration |
WO2010085542A2 (en) | 2009-01-23 | 2010-07-29 | Novartis Ag | Biomarkers related to age-related macular degeneration (amd) |
US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
JP5651527B2 (ja) * | 2011-05-02 | 2015-01-14 | 沖電気工業株式会社 | 無線端末装置、無線通信システム、プログラムおよび無線通信方法 |
-
2009
- 2009-03-27 CR CR20170001A patent/CR20170001A/es unknown
- 2009-04-27 MY MYPI2010004883A patent/MY162350A/en unknown
- 2009-04-27 SI SI200931308T patent/SI2283041T1/sl unknown
- 2009-04-27 SG SG10201608305SA patent/SG10201608305SA/en unknown
- 2009-04-27 JP JP2011507553A patent/JP5636359B2/ja not_active Expired - Fee Related
- 2009-04-27 CN CN201310681246.5A patent/CN103724433B/zh not_active Expired - Fee Related
- 2009-04-27 TW TW106129777A patent/TW201819418A/zh unknown
- 2009-04-27 US US12/430,479 patent/US8273352B2/en not_active Expired - Fee Related
- 2009-04-27 PT PT97395131T patent/PT2283041E/pt unknown
- 2009-04-27 HU HUE09739513A patent/HUE026349T2/en unknown
- 2009-04-27 RU RU2010148423/10A patent/RU2488594C2/ru not_active IP Right Cessation
- 2009-04-27 BR BRPI0907701 patent/BRPI0907701A2/pt not_active Application Discontinuation
- 2009-04-27 PL PL09739513T patent/PL2283041T3/pl unknown
- 2009-04-27 KR KR1020137017779A patent/KR20130084330A/ko not_active Application Discontinuation
- 2009-04-27 EP EP09739513.1A patent/EP2283041B1/en active Active
- 2009-04-27 NZ NZ621103A patent/NZ621103A/en not_active IP Right Cessation
- 2009-04-27 KR KR1020107026550A patent/KR101322027B1/ko active IP Right Review Request
- 2009-04-27 CA CA2908470A patent/CA2908470A1/en not_active Abandoned
- 2009-04-27 PE PE2009000572A patent/PE20091783A1/es active IP Right Grant
- 2009-04-27 AR ARP090101490A patent/AR071510A1/es active IP Right Grant
- 2009-04-27 ES ES09739513.1T patent/ES2552817T3/es active Active
- 2009-04-27 RS RS20150745A patent/RS54405B1/en unknown
- 2009-04-27 CL CL2009001001A patent/CL2009001001A1/es unknown
- 2009-04-27 EP EP15178110.1A patent/EP3002295A1/en not_active Withdrawn
- 2009-04-27 AU AU2009241348A patent/AU2009241348C1/en not_active Ceased
- 2009-04-27 PE PE2013002736A patent/PE20140806A1/es active IP Right Grant
- 2009-04-27 CA CA2720853A patent/CA2720853C/en not_active Expired - Fee Related
- 2009-04-27 MX MX2010011342A patent/MX2010011342A/es active IP Right Grant
- 2009-04-27 DK DK09739513.1T patent/DK2283041T3/da active
- 2009-04-27 EP EP17157837.0A patent/EP3235829B1/en active Active
- 2009-04-27 WO PCT/US2009/041785 patent/WO2009134711A1/en active Application Filing
- 2009-04-27 NZ NZ588457A patent/NZ588457A/xx not_active IP Right Cessation
- 2009-04-27 CN CN200980123668.2A patent/CN102066419B/zh not_active Expired - Fee Related
- 2009-04-27 SG SG2013025630A patent/SG189756A1/en unknown
- 2009-04-27 TW TW103106291A patent/TWI616456B/zh not_active IP Right Cessation
- 2009-04-27 NZ NZ603492A patent/NZ603492A/en not_active IP Right Cessation
- 2009-04-27 TW TW098113922A patent/TWI558413B/zh not_active IP Right Cessation
-
2010
- 2010-10-07 IL IL208555A patent/IL208555A/en active IP Right Grant
- 2010-10-15 MX MX2018013087A patent/MX2018013087A/es unknown
- 2010-11-11 MA MA33342A patent/MA32300B1/fr unknown
- 2010-11-19 CO CO10145550A patent/CO6331346A2/es active IP Right Grant
- 2010-11-26 EC EC2010010637A patent/ECSP10010637A/es unknown
- 2010-11-26 CR CR11817A patent/CR11817A/es unknown
-
2011
- 2011-02-17 HK HK11101560.5A patent/HK1147503A1/xx not_active IP Right Cessation
-
2012
- 2012-05-04 AR ARP120101576A patent/AR086272A2/es unknown
- 2012-08-22 US US13/591,755 patent/US8614306B2/en not_active Expired - Fee Related
-
2013
- 2013-03-06 ZA ZA2013/01709A patent/ZA201301709B/en unknown
- 2013-06-18 JP JP2013128011A patent/JP5931008B2/ja not_active Expired - Fee Related
- 2013-09-20 US US14/033,175 patent/US9676868B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/198,021 patent/US20140212433A1/en not_active Abandoned
- 2014-03-07 PH PH12014500519A patent/PH12014500519B1/en unknown
- 2014-06-27 HK HK14106480.8A patent/HK1193111A1/zh not_active IP Right Cessation
-
2015
- 2015-11-23 US US14/948,911 patent/US20160145349A1/en not_active Abandoned
- 2015-11-23 HR HRP20151259TT patent/HRP20151259T1/hr unknown
- 2015-11-26 CY CY20151101079T patent/CY1116982T1/el unknown
-
2017
- 2017-05-18 US US15/598,735 patent/US20180100024A1/en not_active Abandoned
- 2017-06-19 IL IL253014A patent/IL253014A0/en unknown
-
2018
- 2018-02-28 CL CL2018000537A patent/CL2018000537A1/es unknown
- 2018-04-25 HK HK18105422.7A patent/HK1245812A1/zh unknown
- 2018-07-27 US US16/048,002 patent/US20190185579A1/en not_active Abandoned
-
2019
- 2019-04-15 IL IL266039A patent/IL266039A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
AR077333A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
AR090585A1 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
CR11837A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
AR083715A1 (es) | Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas | |
CO6351802A2 (es) | Anticuerpos para ccr2 | |
AR044388A1 (es) | Moleculas de union a cd20 | |
PE20120586A1 (es) | Proteinas de union a il-1 | |
CU23719A3 (es) | Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
CL2008001620A1 (es) | Induccion de fenotipo tolerogenico en celulas dendriticas maduras | |
UY33222A (es) | Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas | |
AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
SI2970447T1 (en) | PROTITELES AGAINST PAN-ELR + CXC KEMOCIN | |
GT200600209A (es) | Tratamiento de enfermedades usando un sistema mejorado de expresion regulada | |
AR114997A2 (es) | Anticuerpos anti-factor d humanizados y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |